Share

Stephanie Sacharow

M.D.

Director, Harvey Levy Program for Phenylketonuria and Related Conditions

Director, PAL (Phenylalanine Ammonia Lyase) Clinic

Attending Physician, Boston Children’s Hospital

Assistant Professor of Pediatrics, Harvard Medical School

Dr. Stephanie Sacharow is a medical geneticist experienced in the management of patients with a variety of genetic conditions and metabolic disease. She studied Neuroscience at Vanderbilt University prior to attending the University of Miami Miller School of Medicine, and later joining their faculty. Dr. Sacharow is board certified in Pediatrics, Medical Genetics and Medical Biochemical Genetics, and has been practicing over 15 years. She was involved with the implementation and execution of expanded newborn screening for metabolic disease for the South Florida region, and was director of the Cleft Lip and Palate team. Dr. Sacharow was also program director for the genetics training programs, and taught medical school and master’s level courses.  Dr. Sacharow was recruited to Boston Children’s Hospital/Harvard Medical School in 2015.

Dr. Sacharow is the director of the Dr. Harvey Levy Program for Phenylketonuria and Related Conditions, and the medical director of the PAL clinic at Boston Children's Hospital. Dr. Sacharow is team member and provider for the BoLD Lysosomal Storage Disease Program. She has been involved in research studies with a focus on autism, genomic imbalances, inborn errors of metabolism and novel genes for rare disorders. Dr. Sacharow is currently principal investigator and co-investigator in multiple clinical trials for Phenylketonuria and Homocystinuria. She has expertise in the management of patients with pegvaliase (Palynziq), having been an investigator in the clinic trials leading the PAL clinic at Boston Children's Hospital, and co-author of the management guidelines for pegvaliase. She has been an invited speaker at national and international conferences to educate and share the BCH PAL program's experiences and practice improvements.

Stephanie Sacharow

M.D.

Director, Harvey Levy Program for Phenylketonuria and Related Conditions

Director, PAL (Phenylalanine Ammonia Lyase) Clinic

Attending Physician, Boston Children’s Hospital

Assistant Professor of Pediatrics, Harvard Medical School

Dr. Stephanie Sacharow is a medical geneticist experienced in the management of patients with a variety of genetic conditions and metabolic disease. She studied Neuroscience at Vanderbilt University prior to attending the University of Miami Miller School of Medicine, and later joining their faculty. Dr. Sacharow is board certified in Pediatrics, Medical Genetics and Medical Biochemical Genetics, and has been practicing over 15 years. She was involved with the implementation and execution of expanded newborn screening for metabolic disease for the South Florida region, and was director of the Cleft Lip and Palate team. Dr. Sacharow was also program director for the genetics training programs, and taught medical school and master’s level courses.  Dr. Sacharow was recruited to Boston Children’s Hospital/Harvard Medical School in 2015.

Dr. Sacharow is the director of the Dr. Harvey Levy Program for Phenylketonuria and Related Conditions, and the medical director of the PAL clinic at Boston Children's Hospital. Dr. Sacharow is team member and provider for the BoLD Lysosomal Storage Disease Program. She has been involved in research studies with a focus on autism, genomic imbalances, inborn errors of metabolism and novel genes for rare disorders. Dr. Sacharow is currently principal investigator and co-investigator in multiple clinical trials for Phenylketonuria and Homocystinuria. She has expertise in the management of patients with pegvaliase (Palynziq), having been an investigator in the clinic trials leading the PAL clinic at Boston Children's Hospital, and co-author of the management guidelines for pegvaliase. She has been an invited speaker at national and international conferences to educate and share the BCH PAL program's experiences and practice improvements.

Recent Publications

Bone mineral density in participants with phenylalanine hydroxylase (PAH) deficiency: a report from the PHEFREE rare disorders consortium

Published On 2026 Aug 26

Journal article

Low bone mineral density (BMD) in individuals with phenylketonuria (PKU) due to phenylalanine hydroxylase (PAH) deficiency has been variably reported in the medical literature, but the clinical significance of this observation has been uncertain. We measured BMD in a cross-sectional cohort of 117 individuals with PAH deficiency between 6.2 and 56.8 years age who participate in the PHEFREE Consortium Longitudinal Natural History Study. 49% of children under age 18 years and 26% of adults were...


Management of pegvaliase-related skin concerns: best practice recommendations using a modified Delphi approach

Published On 2026 Feb 28

Journal article

CONCLUSIONS: These internationally relevant, evidence-based recommendations provide a structured framework for managing pegvaliase-related skin concerns. Adoption of this guidance may enhance treatment adherence, mitigate adverse events, and ultimately improve patient outcomes.